title: Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?
authors: Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark. pro@steno.dk
authors: Peter
authors: P
authors: Rossing
mesh_terms: D000818:Animals; D017326:Clinical Trials, Phase III as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000401:mortality; D004195:Disease Models, Animal; D057239:Early Termination of Clinical Trials; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D009828:Oleanolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D009828:Oleanolic Acid; C445068:bardoxolone methyl
references: Diabetologia. 1994 May;37(5):511-6
references: 8056190
references: Am J Physiol Renal Physiol. 2011 May;300(5):F1180-92
references: 21289052
references: Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F808-19
references: 23136004
references: Am J Nephrol. 2011;33(5):469-76
references: 21508635
references: Semin Nephrol. 2007 Mar;27(2):172-81
references: 17418686
references: J Pharmacol Exp Ther. 2010 Oct;335(1):2-12
references: 20605904
references: N Engl J Med. 2011 Nov 3;365(18):1746; author reply 1746-7
references: 22047581
references: Diabetologia. 2006 Jan;49(1):11-9
references: 16341685
references: N Engl J Med. 2011 Jul 28;365(4):327-36
references: 21699484